These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 23244208)

  • 1. Can treatment with Cocculine improve the control of chemotherapy-induced emesis in early breast cancer patients? A randomized, multi-centered, double-blind, placebo-controlled Phase III trial.
    Pérol D; Provençal J; Hardy-Bessard AC; Coeffic D; Jacquin JP; Agostini C; Bachelot T; Guastalla JP; Pivot X; Martin JP; Bajard A; Ray-Coquard I
    BMC Cancer; 2012 Dec; 12():603. PubMed ID: 23244208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Herbal medicine for the prevention of chemotherapy-induced nausea and vomiting in patients with advanced colorectal cancer: A prospective randomized controlled trial.
    Wu Z; Fu X; Jing H; Huang W; Li X; Xiao C; Li Z; You F
    J Ethnopharmacol; 2024 May; 325():117853. PubMed ID: 38341113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized trial of individualized versus standard of care antiemetic therapy for breast cancer patients at high risk for chemotherapy-induced nausea and vomiting.
    Clemons M; Dranitsaris G; Sienkiewicz M; Sehdev S; Ng T; Robinson A; Mates M; Hsu T; McGee S; Freedman O; Kumar V; Fergusson D; Hutton B; Vandermeer L; Hilton J
    Breast; 2020 Dec; 54():278-285. PubMed ID: 33242754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy.
    Yeo W; Mo FK; Suen JJ; Ho WM; Chan SL; Lau W; Koh J; Yeung WK; Kwan WH; Lee KK; Mok TS; Poon AN; Lam KC; Hui EK; Zee B
    Breast Cancer Res Treat; 2009 Feb; 113(3):529-35. PubMed ID: 18327706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rolapitant improves quality of life of patients receiving highly or moderately emetogenic chemotherapy.
    Chasen M; Urban L; Schnadig I; Rapoport B; Powers D; Arora S; Navari R; Schwartzberg L; Gridelli C
    Support Care Cancer; 2017 Jan; 25(1):85-92. PubMed ID: 27557833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, double-blind, placebo-controlled study evaluating the efficacy of combination olanzapine, ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving doxorubicin plus cyclophosphamide.
    Tienchaiananda P; Nipondhkit W; Maneenil K; Sa-Nguansai S; Payapwattanawong S; Laohavinij S; Maneechavakajorn J
    Ann Palliat Med; 2019 Sep; 8(4):372-380. PubMed ID: 31500422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, double-blind, placebo-controlled, multicenter study of a ginger extract in the management of chemotherapy-induced nausea and vomiting (CINV) in patients receiving high-dose cisplatin.
    Bossi P; Cortinovis D; Fatigoni S; Cossu Rocca M; Fabi A; Seminara P; Ripamonti C; Alfieri S; Granata R; Bergamini C; Agustoni F; Bidoli P; Nolè F; Pessi MA; Macchi F; Michellini L; Montanaro F; Roila F
    Ann Oncol; 2017 Oct; 28(10):2547-2551. PubMed ID: 28666335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mirtazapine, a dopamine receptor inhibitor, as a secondary prophylactic for delayed nausea and vomiting following highly emetogenic chemotherapy: an open label, randomized, multicenter phase III trial.
    Cao J; Ouyang Q; Wang S; Ragaz J; Wang X; Teng Y; Wang B; Wang Z; Zhang J; Wang L; Wu J; Shao Z; Hu X
    Invest New Drugs; 2020 Apr; 38(2):507-514. PubMed ID: 32036491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial.
    Grunberg SM; Rolski J; Strausz J; Aziz Z; Lane S; Russo MW; Wissel P; Guckert M; Wright O; Herrstedt J
    Lancet Oncol; 2009 Jun; 10(6):549-58. PubMed ID: 19428297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, placebo controlled trials.
    Warr DG; Grunberg SM; Gralla RJ; Hesketh PJ; Roila F; Wit Rd; Carides AD; Taylor A; Evans JK; Horgan KJ
    Eur J Cancer; 2005 Jun; 41(9):1278-85. PubMed ID: 15939263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing the impact of chemotherapy-induced nausea and vomiting on patients' daily lives: a modified version of the Functional Living Index-Emesis (FLIE) with 5-day recall.
    Martin AR; Pearson JD; Cai B; Elmer M; Horgan K; Lindley C
    Support Care Cancer; 2003 Aug; 11(8):522-7. PubMed ID: 12827483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral THC:CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a randomised, placebo-controlled, phase II crossover trial.
    Grimison P; Mersiades A; Kirby A; Lintzeris N; Morton R; Haber P; Olver I; Walsh A; McGregor I; Cheung Y; Tognela A; Hahn C; Briscoe K; Aghmesheh M; Fox P; Abdi E; Clarke S; Della-Fiorentina S; Shannon J; Gedye C; Begbie S; Simes J; Stockler M
    Ann Oncol; 2020 Nov; 31(11):1553-1560. PubMed ID: 32801017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of delayed chemotherapy-induced nausea and vomiting after moderately high to highly emetogenic chemotherapy: comparison of ondansetron, prochlorperazine, and dexamethasone.
    Lindley C; Goodin S; McCune J; Kane M; Amamoo MA; Shord S; Pham T; Yowell S; Laliberte K; Schell M; Bernard S; Socinski MA
    Am J Clin Oncol; 2005 Jun; 28(3):270-6. PubMed ID: 15923800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy: a randomized, double-blind, placebo-controlled study.
    Mizukami N; Yamauchi M; Koike K; Watanabe A; Ichihara K; Masumori N; Yamakage M
    J Pain Symptom Manage; 2014 Mar; 47(3):542-50. PubMed ID: 23856100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of a Standardized Ginger Root Powder Regimen on Chemotherapy-Induced Nausea and Vomiting: A Multicenter, Double-Blind, Placebo-Controlled Randomized Trial.
    Crichton M; Marshall S; Isenring E; Lohning A; McCarthy AL; Molassiotis A; Bird R; Shannon C; Koh A; McPherson I; Marx W
    J Acad Nutr Diet; 2024 Mar; 124(3):313-330.e6. PubMed ID: 37699474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of chemotherapy-induced nausea and vomiting associated with docetaxel and cyclophosphamide in early breast cancer patients and aprepitant efficacy as salvage therapy. Results from the Spanish Breast Cancer Group/2009-02 study.
    Llombart-Cussac A; Ramos M; Dalmau E; García-Saenz JA; González-Farré X; Murillo L; Calvo L; Morales S; Carañana V; González A; Fernández-Morales LA; Moreno F; Casas MI; Angulo Mdel M; Cámara MC; Garcia-Mace AI; Carrasco E; Jara-Sánchez C
    Eur J Cancer; 2016 May; 58():122-9. PubMed ID: 26994459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Netupitant/palonosetron (NEPA) and dexamethasone for prevention of emesis in breast cancer patients receiving adjuvant anthracycline plus cyclophosphamide: a multi-cycle, phase II study.
    Caputo R; Cazzaniga ME; Sbrana A; Torrisi R; Paris I; Giordano M; Montesarchio V; Guarneri V; Amaducci L; Bilancia D; Cilenti G; Fabi A; Collovà E; Schirone A; Bonizzoni E; Celio L; De Placido S; De Laurentiis M
    BMC Cancer; 2020 Mar; 20(1):232. PubMed ID: 32188417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemotherapy-induced nausea and vomiting in daily clinical practice: a community hospital-based study.
    Hilarius DL; Kloeg PH; van der Wall E; van den Heuvel JJ; Gundy CM; Aaronson NK
    Support Care Cancer; 2012 Jan; 20(1):107-17. PubMed ID: 21258948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Casopitant improves the quality of life in patients receiving highly emetogenic chemotherapy.
    Gridelli C; Haiderali AM; Russo MW; Blackburn LM; Lykopoulos K
    Support Care Cancer; 2010 Nov; 18(11):1437-44. PubMed ID: 19882176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Effect of a Standardized Ginger Extract on Chemotherapy-Induced Nausea-Related Quality of Life in Patients Undergoing Moderately or Highly Emetogenic Chemotherapy: A Double Blind, Randomized, Placebo Controlled Trial.
    Marx W; McCarthy AL; Ried K; McKavanagh D; Vitetta L; Sali A; Lohning A; Isenring E
    Nutrients; 2017 Aug; 9(8):. PubMed ID: 28805667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.